Breast Cancer: Targets and Therapy

Breast Cancer Biomarkers in Diagnostic and Translational Pathology

Breast cancer diagnostics has undergone a significant transformation with the expanding integration of immunohistochemistry-based biomarker assessment into routine pathology practice. Beyond traditional morphologic classification, contemporary evaluation increasingly incorporates predictive and prognostic markers. In breast pathology, biomarkers such as hormone receptors and HER2 have long served as foundational tools; however, recent developments have broadened this landscape to include more nuanced categories of expression and emerging targets. This evolving framework reflects a shift toward more refined histopathologic evaluation. As a result, breast cancer pathology now sits at the intersection of diagnostic evaluation and translational science, with biomarker assessment forming a core component of how these tumors are classified and understood.

Breast cancer diagnostics has undergone a significant transformation with the expanding integration of immunohistochemistry-based biomarker assessment into routine pathology practice. Beyond traditional morphologic classification, contemporary evaluation increasingly incorporates predictive and prognostic markers. In breast pathology, biomarkers such as hormone receptors and HER2 have long served as foundational tools; however, recent developments have broadened this landscape to include more nuanced categories of expression and emerging targets. This evolving framework reflects a shift toward more refined histopathologic evaluation. As a result, breast cancer pathology now sits at the intersection of diagnostic evaluation and translational science, with biomarker assessment forming a core component of how these tumors are classified and understood.

This Article Collection will focus on investigating immunohistochemical and molecular biomarker testing in breast cancer, with particular emphasis on optimizing reproducibility and standardization in routine practice.

Topics of interest include (but are not limited to):

• Technical and interpretative challenges that pathologists and oncologists must consider, especially in the assessment of low and ultra-low HER2 expression and their implications for targeted therapies.
• Predictive biomarkers in breast cancer immunotherapy, as well as emerging markers that inform treatment selection and response.
• Integration of digital pathology approaches and translational surgical pathology studies.

Dr. Eyas Alzayadneh is a surgical pathologist with training in gynecologic and breast pathology. His work focuses on the integration of histopathologic, immunohistochemical, and molecular features in tumor evaluation and clinical practice. He has contributed to research across multiple areas of cancer pathology, with an interest in biomarker-based diagnostics and their clinical applications.

Dr. Rofieda Radi Abdel Rahman Alwaqfi is an Assistant Professor of Pathology at the Johns Hopkins Hospital.

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this Collection will not be handling the manuscripts (unless they are an Editorial Board member).

Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31st December 2026.

Please contact Rebecca Turner at rebecca.turner@tandf.co.uk with any questions or requests for discount codes relating to this Article Collection.

Please be sure to select the appropriate Article Collection from the drop-down menu in the submission system.